Literature DB >> 7615177

[The echographic diagnosis of neurogenic paraosteoarthropathies in myelosis patients].

C Pistarini1, S Carlevati, A Contardi.   

Abstract

To assess the role of the ultrasonic imaging evaluation of articular lesions suspected to be the initial presentation of heterotopic ossifications (HO) 59 consecutive spinal cord injured patients were studied. 32 out of 59 patients showed clinical signs of local inflammation in one of the articular sites of the upper or lower limbs, sonographic scans proved to be diagnostic of HO in 7 out of those 32 patients before a their radiographic findings. Serial sonographic examinations were performed utilising a 7.5 MegaHertz transducer probe for 2 months. The imaging abnormalities were correlated with biochemical levels of serum alkaline phosphatase, modifications of radiographic features and bone 99mTC scintigraphy. Scintigraphy revealed to have a high sensitivity but a low specificity for the diagnosis of HO. Also the serum levels of alkaline phosphatase was not a sensitive indicator of early HO in our group of patients. Moreover serial sonographic scans confidently excluded the HO in the 25 patients with no initial signs of the disease without any false negative results. Thus, early sonographic assessment of patients with spinal cord injury in which local signs of inflammation suggest initial HO formation revealed to be superior to the other utilized technique for the diagnosis of HO and may be considered a valuable alternative in particular to evaluate the evolutive pattern of this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7615177

Source DB:  PubMed          Journal:  G Ital Med Lav        ISSN: 0391-9889


  1 in total

1.  The sensitivity of ultrasound screening examination in detecting heterotopic ossification following spinal cord injury.

Authors:  T Rosteius; E M Suero; D Grasmücke; M Aach; A Gisevius; M Ohlmeier; R Meindl; T A Schildhauer; M Citak
Journal:  Spinal Cord       Date:  2016-06-28       Impact factor: 2.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.